Cardiac Biomarkers in Preeclampsia: Prediction of Disease and the Risk of Future Cardiovascular Events in Survivors

Launched by BABCOCK UNIVERSITY · Jul 8, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how to predict and identify women at risk for heart problems after experiencing preeclampsia during pregnancy. Preeclampsia is a condition that can occur during pregnancy and is linked to inflammation and blood vessel changes, which may lead to serious heart issues later in life, like heart attacks or strokes. Researchers want to find early signs of preeclampsia and measure certain blood markers and genes to help detect these risks.

Women who are healthy and pregnant under 20 weeks, those diagnosed with preeclampsia between 20 to 41 weeks, and women less than one year postpartum who have had preeclampsia or eclampsia may be eligible to participate. Participants will have blood tests and regular follow-ups for up to five years to track their health. This trial is important because it aims to help identify women who may need extra care to prevent future heart disease, ultimately improving their long-term health.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Healthy pregnant women at gestational age less than 20 weeks
• • Women with diagnosis of preeclampsia at gestational age 20-41 weeks
• • Healthy pregnant women without preeclampsia at gestational age 20-41 weeks
• • Women less than one year postpartum with history of preeclampsia or eclampsia in index pregnancy
• • Healthy women less than 1 year postpartum with no previous history of preeclampsia or eclampsia
• Exclusion Criteria:
• • History of chronic hypertension or hypertension before pregnancy
• • Patients with cardiac disease
• • Patients with renal disease
• • Patients with diabetes mellitus
• • Patients with connective tissue disorders